(JAMA) Rituximab vs ocrelizumab in RRMS on: June 12, 2023, 10:09:55 am #1 From JAMA Neurology (June 12, 2023)--"Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis":https://bit.ly/43BuNIb Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
Ocrevus appears better than rituximab at preventing MS relapses Reply #1 on: June 15, 2023, 08:44:53 pm #2 From Multiple Sclerosis News Today (June 14, 2023)--"Ocrevus appears to be better than rituximab at preventing MS relapses": Ocrevus appears better than rituximab in preventing MS relapses |... Ocrevus is more effective than rituximab at reducing relapse activity of RRMS, while disability progression is comparable, a study suggests. Multiple Sclerosis News Today · multiplesclerosisnewstoday.com Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
(JAMA editorial) New approaches to challenge old assumptions: B-cell depletion in MS Reply #2 on: June 19, 2023, 09:50:50 pm #3 This JAMA editorial discusses this study.From JAMA (June 12, 2023), "New Approaches to Challenge Old Assumptions: B-Cell Depletion in Multiple Sclerosis":https://bit.ly/3p9SU1D Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
Re: (JAMA) Rituximab vs ocrelizumab in RRMS--variations in real-world experience Reply #3 on: November 20, 2023, 09:20:41 pm #4 Some MS researchers have written a letter about the article mentioned in the first post in this thread, and the author of that article has replied.In JAMA Neurology (November 20, 2023), "Comment and Response"--"Comparative efficacy of disease-modifying treatments for multiple sclerosis--Variations in real-world experience":https://bit.ly/3SR9zn0And the author's reply in the same issue:https://tinyurl.com/mtrwpcxt Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
(JAMA) Potential Medicare and Medicaid savings on anti-CD20 therapy for MS (Rituxan vs. Ocrevus) Reply #4 on: November 27, 2023, 04:18:36 pm #5 And then there is the matter of the comparative cost of these two drugs.From JAMA (Research Letter, November 27, 2023)--"Potential Medicare and Medicaid savins on anti-CD20 therapy for multiple sclerosis":https://tinyurl.com/v3zknrnn Logged MS Speaks--online for 20 yearsSPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) 12/16/20 - 3/16/24.
